Popular Trials
Antiplatelet Agent
Clopidogrel +2 More for Coronary Artery Disease
Recruiting4 awardsPhase 4
Cleveland, Ohio
CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)
Clopidogrel and Aspirin for Coronary Artery Disease
Recruiting1 award3 criteria
Baltimore, Maryland
Purpose: In patients with coronary artery disease, aspirin and Plavix are used increasingly to prevent the formation of blood clots in the coronary arteries. These drugs exert their beneficial effects by irreversibly blocking platelets, the compounds found in blood responsible for clotting after an injury or during a heart attack. However, these effects also place patients at increased risk for bleeding after coronary artery bypass surgery. Therefore, it is currently recommended to withhold Plavix therapy for 5 days before undergoing surgery in order to reduce the incidence of bleeding. However, it has been repeatedly shown that Plavix exerts variable effects on different patients, which may be partially explained by poor absorption, drug-drug interaction, and by variations in deoxyribonucleic acid (DNA) which constitutes your genes. In addition, the time required for platelets to regain function after Plavix treatment has been shown to vary between patients. Therefore, by measuring platelet function, it may be possible to determine the optimal amount of time required to withhold Plavix before undergoing bypass surgery, which may improve rates of bleeding following the procedure. The purpose of this study is to classify patients into groups based on platelet function in order to define the ideal time period for delaying surgery. By analyzing the amount of time required for platelet recovery, it is expected that surgery-related bleeding will decrease without increasing the risk of blood clot formation. Eligibility: Approximately 200 patients requiring CABG will be enrolled at Sinai Hospital, which is the only site where this study is being conducted. To be eligible you must: * Be able to provide written informed consent. * Be between the ages of 18-85 and require CABG. * Currently be on aspirin therapy (81-325mg).
P2Y12 Inhibitor
Ticagrelor vs Clopidogrel for Coronary Artery Disease
Recruiting3 awardsPhase 4
Jacksonville, Florida
This trial is testing whether the drug ticagrelor is more effective than clopidogrel in reducing the risk of thrombotic events (blood clots) in patients who are also taking oral anticoagulants (blood thinners). A total of 63 patients will be enrolled and given either ticagrelor or clopidogrel. The trial will assess the pharmacodynamic effects of both drugs to determine which is more effective.
Popular Filters
Phase 3 Trials
P2Y12 receptor antagonist
Low-Dose Ticagrelor for Acute Coronary Syndrome
Recruiting4 awardsPhase 3
San Diego, California
This trial looks at whether a lower dose of the drug ticagrelor is just as effective as the conventional dose in preventing atherothrombotic events (heart attacks and strokes) in patients with acute coronary syndromes, with a particular focus on East Asian patients.
P2Y12 receptor inhibitor
ticagrelor +1 More for Coronary Artery Disease
Recruiting3 awardsPhase 2 & 3
Havertown, Pennsylvania
With the widespread use of clopidogrel, resistance to clopidogrel has been attracting increasing attention, and emerged as a new challenge adversely affecting patients clinical risk and outcome. Clopidogrel resistance means that blood platelets show little or no response to clopidogrel. It is closely associated with increased risk of serious cardiovascular events, seriously affects the prognosis of patients, and brings difficulties to clinical treatment. Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. But it is still not very clear that the effect of low-dose ticagrelor on platelet function in patients with clopidogrel resistance and coronary heart disease. Therefore, we performed this randomized, single-blind clinical trial to observe the effects of low-dose ticagrelor and double standard-dose clopidogrel on platelet aggregation and prognosis in clopidogrel resistance's patients with coronary heart disease.
Mechanical Thrombectomy Device
Thrombectomy + Angioplasty/Stenting for Stroke
Recruiting2 awardsPhase 3
Toledo, Ohio
This trial tests if using a stent to open a blocked neck artery along with removing a brain clot is better than just removing the clot alone for stroke patients with severe artery blockages.
Trials With No Placebo
Fibrinolytic
Tenecteplase +2 More for Heart Attack
Recruiting5 awardsPhase 4
Edmonton, Alberta
This trial compares two treatments for heart attack patients aged 60 and older. One treatment uses medications to dissolve clots and prevent new ones, followed by procedures if needed. The other treatment uses a procedure to open blocked arteries directly. The goal is to determine which approach is safer and more effective.
P2Y12 Receptor Antagonist
low-dose ticagrelor +1 More for Coronary Artery Disease
Recruiting5 awardsPhase 4
San Diego, California
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy (DAPT) have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for patients who have an ACS with or without ST-segment elevation. However, few East Asian patients (or those of East Asian descent) have been included in these trials to assess the use of these drugs. In Korea and Japan, it has been reported that low doses of ticagrelor might have a more potent inhibition of platelet aggregation (IPA) than clopidogrel (75 mg once daily) in healthy subjects and patients with stable coronary artery disease, respectively. But it is still not clear whether a low dose of ticagrelor is superior to clopidogrel in a large population of Chinese ACS patients. A recent study on pharmacokinetics and tolerability of ticagrelor has found that maximum plasma concentration and area under the plasma concentration-time curve of ticagrelor (90 mg twice daily) and its active metabolite (AR-C124910XX) tended to be approximately 40% higher in healthy Chinese volunteers compared with Caucasian subjects. This data also suggested that a low dose of ticagrelor might be more appropriate for Chinese ACS patients. In view of a large diurnal variation with a single daily dose, a lower dose twice daily may be a better choice for Chinese patients. Therefore, the investigators performed this randomized, single-blind, crossover clinical trial to observe the efficacy and safety of low-dose ticagrelor (22.5 mg twice daily) in comparison to clopidogrel (75mg once daily) in Chinese patients with stable coronary artery disease.
P2Y12 receptor antagonist
Low-Dose Ticagrelor for Acute Coronary Syndrome
Recruiting4 awardsPhase 3
San Diego, California
This trial looks at whether a lower dose of the drug ticagrelor is just as effective as the conventional dose in preventing atherothrombotic events (heart attacks and strokes) in patients with acute coronary syndromes, with a particular focus on East Asian patients.
Antiplatelet Agent
Clopidogrel +1 More for Coronary Artery Disease
Recruiting3 awards4 criteria
Roslyn, New York
* The purpose of this study is to determine the level of inhibition of platelet activation of an approved thienopyridine(clopidogrel or prasugrel) and aspirin regimen in the setting of drug eluting coronary stent implantation. * In subjects with high residual levels of platelet reactivity after receiving either a maintenance or loading dose of either clopidogrel or prasugrel, a cross over of thienopyridine treatment to the alternate medication will occur. * The study tests the hypothesis that adequate platelet inhibition will occur in subjects who have high levels of platelet reactivity and are subsequently switched from clopidogrel to prasugrel(loading or maintenance dose) without increased episodes of bleeding or MACE events at discharge and 30 days post Percutaneous Coronary Intervention (PCI).
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.